Ultragenyx (RARE) Rockets 15.5% on Bargain-Hunting After Steep Fall

We precocious published 10 Stocks connected Fire Ahead of 2026. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is 1 of the champion performers connected Tuesday.

Ultragenyx rebounded by 15.52 percent connected Tuesday to adjacent astatine $22.78 apiece arsenic investors resorted to bargain-hunting pursuing the erstwhile day’s steep 46 percent fall, dragged by disappointing objective proceedings results for its brittle bony illness treatment.

In a connection connected Monday, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said that 2 of its signifier 3 objective trials to trial the efficacy of setrusumab failed to execute statistical value successful reducing yearly objective fracture complaint arsenic compared to placebo and bisphosphonates.

Both studies, however, achieved the secondary endpoints of improvements successful bony mineral density (BMD) against comparators.

“We are amazed and disappointed by these results, fixed the promising information from our Phase 2 survey and the deficiency of approved attraction options disposable to patients with OI (Osteogenesis Imperfecta) who unrecorded with important pain, disability, and illness burden,” said Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) President and CEO Emil Kakkis.

“We proceed to research the information to summation a deeper knowing of the findings,” helium added.

The institution would behaviour further analyses connected the information crossed some studies, including connected different bony wellness and objective endpoints beyond fractures, to measure adjacent steps for the program.

“While we are disappointed by these results, we proceed to physique our commercialized gross from 4 approved products and hole for a transformational twelvemonth up with perchance 2 near-term cistron therapy launches and a pivotal Phase 3 readout successful Angelman syndrome,” Kakkis said.

While we admit the imaginable of RARE arsenic an investment, our condemnation lies successful the content that immoderate AI stocks clasp greater committedness for delivering higher returns and person constricted downside risk. If you are looking for an highly inexpensive AI banal that is besides a large beneficiary of Trump tariffs and onshoring, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.